AVXL Anavex Life Sciences Corp.
Healthcare$2.71+0.56%ClosedMarket Cap: $251.1M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.89
P/S
0.00
EV/EBITDA
-2.95
DCF Value
$1.17
FCF Yield
-13.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-38.8%
ROA
-30.0%
ROIC
-35.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-6.8M | $-5.7M | $— | — |
| Q4 null | $0.00 | NaN% | $-10.8M | $-9.8M | $— | — |
| FY null | $0.00 | NaN% | $-51.4M | $-46.4M | $— | — |
| Q3 null | $0.00 | NaN% | $-14.5M | $-13.2M | $— | — |
| Q2 null | $0.00 | NaN% | $-12.5M | $-11.2M | $— | — |
| Q1 null | $0.00 | NaN% | $-13.6M | $-12.1M | $— | — |
| Q4 null | $0.00 | NaN% | $-14.3M | $-11.6M | $— | — |
| FY null | $0.00 | NaN% | $-52.9M | $-43.0M | $— | — |
| Q3 null | $0.00 | NaN% | $-14.6M | $-12.2M | $— | — |
| Q2 null | $0.00 | NaN% | $-12.6M | $-10.5M | $— | — |
| Q1 2024 | $0.00 | NaN% | $-11.4M | $-8.6M | $-0.10 | — |
| Q4 2023 | $0.00 | NaN% | $-12.7M | $-10.1M | $-0.13 | — |